Associations between public health indicators and injecting prescription opioids by prescription opioid abusers in substance abuse treatment
Abstract
Objective: To determine what, if any, public health and societal impacts are associated specifically with injection of prescription opioids. Design: Cross-sectional observational study. Setting: Five hundred forty treatment facilities in 35 states across the United States performing Addiction Severity Index-Multimedia Version (ASI-MV) assessments. Participants: Adult patients (29,459) who reported past 30-day abuse of any prescription opioid on the ASI-MV assessment between January 2007 and January 2011. Main outcome measures: The public health indicators selected for this study were liver disease, HIV/AIDS status, recent visit to an emergency room, treatment for pain, treatment for overdosing, homelessness, residence with alcohol/substance abuser, and unemployment. Results: Prescription opioid injection was significantly associated with health problems, psychosocial problems, and utilization of medical services. Conclusions: This study demonstrates an approach to measure the potential impact of injecting prescription opioids on public health indicators. Findings indicate a positive association between injection of prescription opioids and public health indicators suggesting a need for prescription opioid formulations that may inhibit injection of these medications. Keywords: prescription drug injection, public health, correlates DOI:10.5055/jom.2013.0142
References
Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10: 113-130.
Institute of Medicine of The national Academies: Relieving Pain in America, A blueprint for Transforming Prevention, Care, Education, and Research. 2011. Report Brief, June. Available at
www.iom.edu/relievingpain. Accessed June 29, 2011.
Brennan F, Carr DB, Cousins M, et al.: Pain management: A fundamental human right. Anesth Analg. 2007; 105: 205-221.
Reidenberg MM, Willis O: Prosecution of physicians for prescribing opioids to patients. Clin Pharmacol Ther. 2007; 81(6):903-906.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Detailed Tables, 2009 National Survey on Drug Use & Health. 2010. Available at http://oas.samhsa.
gov/WebOnly.htm#NSDUHtabs. Accessed September 2011.
Katz N: Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep. 2008; 10(1): 11-18.
Raffa RB, Pergolizzi JV Jr: Opioid formulations designed to resist/deter abuse. Drugs. 2010; 70(13): 1657-1675.
Compton WM, Volkow ND: Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006; 83(suppl 1):S4-S7.
National Institute on Drug Abuse: Prescription and over-thecounter medications (NIDA InfoFacts). 2009. Available at http://www.nida.nih.gov/PDF/Infofacts/PainMed09.pdf. Accessed December 2012.
Katz N, Dart RC, Bailey E, et al.: Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37(4): 205-217.
Sherman SG, Cheng Y, Kral AH, et al.: Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city. Drug Alcohol Depend. 2007; 88(2-3): 182-187.
Milloy MJ, Kerr T, Mathias R, et al.: Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse. 2008; 34(4): 499-509.
Stoové MA, Dietze PM, Aitken CK, et al.: Mortality among injecting drug users in Melbourne: A 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend.2008; 96(3): 281-285.
Vlahov D, Wang C, Ompad D, et al.: Collaborative Injection Drug User Study. Mortality risk among recent-onset injection drug users in five U.S. Cities. Subst Use Misuse. 2008; 43(3-4): 413-428.
Disney E, Kidorf M, Kolodner K, et al.: Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants. J Nerv Ment Dis. 2006; 194: 577-583.
Aceijas C, Rhodes T: Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007; 18(5): 352-358.
Neaigus A, Miller M, Friedman SR, et al.: Potential risk factors for the transition to injecting among non-injecting heroin users: A comparison of former injectors and never injectors. Addiction. 2001; 96: 847-860.
Green TC, Butler SF: A latent class analysis of Rx opioid abuse in the National Addictions Vigilance Intervention & Prevention Program (NAVIPPRO™). San Juan, Puerto Rico: College on Drug Dependence, 2008.
Green TC, Black R, Grimes Serrano JM, et al.: Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatment. PLoS One. 2011; 6(11): e27244.
Marshall BD, Fairbairn N, Li K, et al.: Physical violence among a prospective cohort of injection drug users: A genderfocused approach. Drug Alcohol Depend. 2008; 97(3): 237-246.
Young AM, Havens JR, Leukefeld CG, et al.: Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduct J. 2010; 7: 24.
Butler SF, Black R, Grimes Serrano JM, et al.: Characteristics of prescription opioid abusers in treatment: Opioid use history, age, use patterns, and functional severity. J Opioid Manag. 2010; 6(4): 230-252.
Butler SF, Budman SH, Licari A, et al.: National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™): A real-time, product-specific, public health surveillance system for monitoring Rx drug abuse. Pharmacoepidemiol Drug Saf. 2008; 17(12): 1142-1154.
Hendricks VM, Kaplan CD, VanLimbeek J, et al.: The Addiction Severity Index: Reliability and validity in a Dutch addict population. J Subst Abuse Treat. 1989; 6: 133-141.
Kosten TR, Rounsaville BJ, Kleber HD, et al.: Concurrent validity of the Addiction Severity Index. J Nerv Ment Dis. 1983; 171(10): 606-610.
McLellan AT, Luborsky L, Woody GE, et al.: An improved diagnostic evaluation instrument for substance abuse patients. J Nerv Ment Dis. 1980; 168: 26-33.
McLellan AT, Kushner H, Metzger D, et al.: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9(3): 199-213.
Butler SF, Budman SH, Goldman RJ, et al.: Initial validation of a computer-administered Addiction Severity Index: The ASIMV. Psychol Addict Behav. 2001; 15(1): 4-12.
Butler SF, Redondo JP, Fernandez KC, et al.: Validation of the Spanish Addiction Severity Index Multimedia Version (SASI-MV). Drug Alcohol Depend. 2009; 99(1-3): 18-27.
McGahan PL, Griffith JA, Parente R, et al.: Composite Scores from the Addiction Severity Index. Philadelphia, PA: Department of Veterans Affairs Medical Center, 1986.
Katz NP, Adams EH, Chilcoat H, et al.: Challenges in the development of prescription opioid abuse-deterrent formulations.Clin J Pain. 2007; 8: 648-660.
Kleinbaum DG, Kupper LL, Nizam A, and et al.: Applied Regression Analysis and Other Multivariable Methods. 4th ed. Pacific Grove: Duxbury Press/Cengage Learning, 2008.
Neaigus A, Gyarmathy VA, Miller M, et al.: Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend. 2007; 89(2-3): 234-243.
Hall AJ, Logan JE, Toblin RL, et al.: Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008; 300(22): 2613-2620.
US FDA: FDA Approves New Formulation for Oxycontin. April 5, 2010. 2010. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm. Accessed April 5, 2010.
Pain Therapeutics Inc.: FDA Complete Response Letter Received for REMOXY. June 24, 2011. Available at http://www.paintrials.com/publications/PR24June2011CRL.pdf. Accessed June 24, 2011.
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
